| Literature DB >> 36163500 |
Ryan D Miller1, Akira Iinishi1, Seyed Majed Modaresi2, Byung-Kuk Yoo3, Thomas D Curtis1, Patrick J Lariviere1, Libang Liang1, Sangkeun Son1, Samantha Nicolau1, Rachel Bargabos1, Madeleine Morrissette1, Michael F Gates1, Norman Pitt1, Roman P Jakob2, Parthasarathi Rath2, Timm Maier2, Andrey G Malyutin4, Jens T Kaiser4, Samantha Niles1, Blake Karavas1, Meghan Ghiglieri1, Sarah E J Bowman5, Douglas C Rees3,6, Sebastian Hiller7, Kim Lewis8.
Abstract
Discovery of antibiotics acting against Gram-negative species is uniquely challenging due to their restrictive penetration barrier. BamA, which inserts proteins into the outer membrane, is an attractive target due to its surface location. Darobactins produced by Photorhabdus, a nematode gut microbiome symbiont, target BamA. We reasoned that a computational search for genes only distantly related to the darobactin operon may lead to novel compounds. Following this clue, we identified dynobactin A, a novel peptide antibiotic from Photorhabdus australis containing two unlinked rings. Dynobactin is structurally unrelated to darobactins, but also targets BamA. Based on a BamA-dynobactin co-crystal structure and a BAM-complex-dynobactin cryo-EM structure, we show that dynobactin binds to the BamA lateral gate, uniquely protruding into its β-barrel lumen. Dynobactin showed efficacy in a mouse systemic Escherichia coli infection. This study demonstrates the utility of computational approaches to antibiotic discovery and suggests that dynobactin is a promising lead for drug development.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36163500 DOI: 10.1038/s41564-022-01227-4
Source DB: PubMed Journal: Nat Microbiol ISSN: 2058-5276 Impact factor: 30.964